Soligenix, Inc. (SNGX) Submits Contract Proposal for Multi-Million Dollar Contract with BARDA
Soligenix, a development stage biopharmaceutical company focused on treatments for gastrointestinal diseases, has submitted a full contract proposal to the Biomedical Advanced Research and Development Authority (BARDA) Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasures. This submission is in regards to a potential multi-year, multi-million dollar contract to develop OrbeShield as a medical countermeasure (MCM) to treat gastrointestinal acute radiation syndrome (GI ARS), a condition that can occur after toxic radiation exposure. BARDA invited Soligenix to submit its proposal in response to a Broad Agency Announcement for advanced research and development and eventual licensure/approval of effective MCMs to…